Corpus overview


Overview

MeSH Disease

Human Phenotype

Falls (1)


Transmission

Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Evaluation of antibody testing SERO for SARS-Cov-2 using ELISA SERO and lateral flow immunoassays SERO

    Authors: Emily R Adams; Mark Ainsworth; Rekha Anand; Monique I Andersson; Kathryn Auckland; J Kenneth Baillie; Eleanor Barnes; Sally Beer; John Bell; Tamsin Berry; Sagida Bibi; Miles Carroll; Senthil Chinnakannan; Elizabeth Clutterbuck; Richard J Cornall; Derrick W Crook; Thushan De Silva; Wanwisa Dejnirattisai; Kate E Dingle; Christina Dold; Alexis Espinosa; David W Eyre; Helen Farmer; Maria Fernandez Mendoza; Dominique Georgiou; Sarah J Hoosdally; Alistair Hunter; Katie Jeffrey; Paul Klenerman; Julian Knight; Clarice Knowles; Andrew J Kwok; Ullrich Leuschner; Robert Levin; Chang Liu; Cesar Lopez-Camacho; Jose Carlos Martinez Garrido; Philippa C Matthews; Hannah McGivern; Alexander J Mentzer; Jonathan Milton; Juthathip Mongkolsapaya; Shona C Moore; Marta S Oliveira; Fiona Pereira; Elena Perez Lopez; Timothy Peto; Rutger J Ploeg; Andrew Pollard; Tessa Prince; David J Roberts; Justine K Rudkin; Veronica Sanchez; Gavin R Screaton; Malcolm G Semple; Donal T Skelly; Jose Slon-Campos; Elliot Nathan Smith; Alberto Jose Sobrino Diaz; Julie Staves; David Stuart; Piyada Supasa; Tomas Surik; Hannah Thraves; Pat Tsang; Lance Turtle; A Sarah Walker; Beibei Wang; Charlotte Washington; Nicholas Watkins; James Whitehouse

    doi:10.1101/2020.04.15.20066407 Date: 2020-04-20 Source: medRxiv

    ABSTRACT Objectives: The COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody SERO detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance SERO of ELISA SERO and lateral flow immunoassay SERO (LFIA) devices. Design: We tested plasma SERO for COVID (SARS-CoV-2) IgM and IgG antibodies SERO by ELISA SERO and using nine different LFIA devices. Setting: We performed laboratory work at the University of Oxford. Participants: We used a panel of plasma SERO samples from individuals who have had confirmed COVID infection MESHD based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142). Main outcome measures: We recorded optical density results from ELISA SERO experiments and positive/negative/invalid results from LFIA devices. Results: ELISA SERO detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection MESHD ( sensitivity SERO 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested [≥]10 days after symptom onset TRANS ( sensitivity SERO 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset TRANS and began to fall HP by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity SERO of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA SERO, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance SERO of most LFIA devices was similar. Conclusions: Currently available commercial LFIA devices do not perform sufficiently well for individual patient applications. ELISA SERO can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.